Peleg I I, Lubin M F, Cotsonis G A, Clark W S, Wilcox C M
Department of Medicine, University of Iowa Hospitals and Clinics, Iowa City 52246, USA.
Dig Dis Sci. 1996 Jul;41(7):1319-26. doi: 10.1007/BF02088554.
Our objective was to study the relationship between dispensed aspirin, nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs), steroidal antiinflammatory drugs (SAIDs), acetaminophen, calcium, psyllium, and multivitamin preparations and the risk for subsequent colorectal adenoma and adenocarcinoma. The design was a case-control study. The patient population was from a large municipal teaching hospital in Atlanta, Georgia. In logistic regression models, the risk of colorectal adenoma or adenocarcinoma decreased in the first two years of continuous NSAID use in a linear, time-dependent manner. The risk of colorectal neoplasia after two years of continuous NSAID use was reduced significantly (P < 0.01) as compared to nonusers. Risk reduction appeared greater for adenocarcinoma than adenoma. The use of SAIDs, calcium, multivitamins, and psyllium, as prescribed to our patient population during the mean six-year study period, conferred no measurable risk reduction. These results suggest that in prospective chemoprevention trials, a significant risk reduction can be expected after only two years of aspirin use, in doses similar to those recommended for the prevention of cardiovascular disease, or nonaspirin NSAIDs [correction of nonaspirin. NSAIDs], in doses commonly prescribed for the management of musculoskeletal pain. The results also imply that any short-term reduction in the incidence of colorectal adenoma detected in a phase II trial would underestimate the chemopreventive effect of NSAIDs on the risk of adenocarcinoma.
我们的目的是研究阿司匹林、非阿司匹林非甾体抗炎药(NSAIDs)、甾体抗炎药(SAIDs)、对乙酰氨基酚、钙、车前草和多种维生素制剂的使用与后续结直肠腺瘤和腺癌风险之间的关系。研究设计为病例对照研究。患者群体来自佐治亚州亚特兰大市的一家大型市立教学医院。在逻辑回归模型中,持续使用NSAIDs的前两年,结直肠腺瘤或腺癌的风险以线性、时间依赖性方式降低。与未使用者相比,持续使用NSAIDs两年后结直肠肿瘤形成的风险显著降低(P < 0.01)。腺癌的风险降低似乎比腺瘤更大。在平均为期六年的研究期间,按照给我们患者群体的处方使用SAIDs、钙、多种维生素和车前草,并未带来可测量的风险降低。这些结果表明,在前瞻性化学预防试验中,仅使用两年与预防心血管疾病推荐剂量相似的阿司匹林,或常用剂量的用于治疗肌肉骨骼疼痛的非阿司匹林NSAIDs [纠正:非阿司匹林NSAIDs],就可预期显著降低风险。这些结果还意味着,在II期试验中检测到的结直肠腺瘤发病率的任何短期降低,都会低估NSAIDs对腺癌风险的化学预防作用。